Navigation Links
MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results
Date:8/3/2009

2009 and reimbursements for UDB-related development expenses, pursuant to MAP Pharmaceuticals' license agreement with AstraZeneca AB. On July 8, 2009, the company received notice from AstraZeneca of the termination of the license agreement, effective immediately. As a result, the remaining unamortized deferred revenue of $33.1 million will be recognized as collaboration revenue in the third quarter of fiscal 2009.

Research and development expenses for the quarter and six months ended June 30, 2009 were $9.6 million and $23.7 million, respectively, compared to $13.0 million and $24.8 million, respectively, for the same periods in 2008. The decreases in research and development expenses were driven primarily by decreases in clinical and other project expenses to support the UDB Phase 3 clinical program, partially offset by increases in clinical and other project expenses to support the LEVADEX Phase 3 clinical program, and in personnel-related expenses to support these clinical programs.

Sales, general and administrative expenses for the quarter and six months ended June 30, 2009 were $3.4 million and $6.2 million, respectively, compared to $3.2 million and $6.3 million, respectively, for the same periods in 2008. For the three months ended June 30, 2009 compared to the same period in 2008, the increase was related primarily to increases in personnel-related expenses, stock-based compensation and other miscellaneous fees.

MAP Pharmaceuticals had cash, cash equivalents and short-term investments as of June 30, 2009 of $54.8 million, compared to $44.7 million as of December 31, 2008. In addition, accounts receivables were $5.1 million at June 30, 2009, compared to $0 at December 31, 2008, due to the collaboration with AstraZeneca.

For the quarter and six months ended June 30, 2009, non-cash share-based compensation and depreciation were approximately $1.7 million and $3.3 million, respectiv
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2014)... CA (PRWEB) August 23, 2014 ... trading system created by Greg Marks has been generating ... earlier this month. The commotion surrounding the new product ... an investigative review. , “In recent years ... trading software systems, commonly referred to as robots or ...
(Date:8/23/2014)... August 23, 2014 GBI Research, the ... “Critical Care Therapeutics in Major Developed Markets to 2020 ... to Drive Market”, which provides in-depth analysis of the ... Italy, Spain, Japan and Canada. The report provides an ... forecasts to 2020. It covers critical care indications that ...
(Date:8/23/2014)... August 23, 2014 Professional kitchen employees, ... study aid in preparing for Food Safety Certification exams ... by Dynamic Path. , Dynamic Path announced the ... includes more than 200 review questions for culinary industry ... designed to cover requirements of the ServSafe® Food Safety ...
(Date:8/23/2014)... Young adults in Athens, GA who find that they have a ... and call the new helpline which can offer support and guidance ... Teen Athens is a wonderful resource for an adolescent drug or ... to end substance abuse once and for all. When a young ... peers when really they should put their faith in a youth ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 Youth substance ... Texas. It’s no different in Houston, TX. Substance abuse ... falling victim to drug and alcohol dependency in higher ... looking to beat substance abuse, but don’t know where ... treatment facility can be a challenge because most treatment ...
Breaking Medicine News(10 mins):Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:Teenagers in Athens, GA are Locating Addiction Recovery Thanks to New Helpline 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... affecting Calcutta has arrived in Delhi and three deaths have ... weeks. //, ,In 2003 there were more than 30 ... reported. , ,N.K. Yadav, deputy health officer, Municipal Corporation ... control. They have hired 1,055 more health workers to check ...
... Cancer Institute had discovered a new molecular explanation for ... the disease called porphyria, the disease that was probably ... ,The Dana-Farber scientists say in a report featured ... the journal Cell that the nutritional component of porphyria ...
... a as paranormal phenomena, may in fact have their roots ... the high incidence of OBE among the general public, not ... of the population have an out-of-body experience (OBE) at some ... physical body from the outside. It isn't uncommon for people ...
... Indian Biotech Company, Biocon to colloborate with Nobex ... oral peptide drug for cardiovascular diseases. The spokesperson ... into global research collaboration // on Tuesday for ... cardiovasculoar diseases. The Biocon press release said, “The ...
... in the September issue of the Harvard Health Letter, ... quick and short working out sessions may not help ... can lead to diseases. To prevent weight gain and ... sessions are required every week. ,Furthermore, some ...
... infection of newborns with herpes type 1 and 2 ... is not an established procedure in most cases., ... the // journal Sexually Transmitted Diseases, researchers in herpes ... STD in Seattle, point out that unlike all comparable ...
Cached Medicine News:Health News:Study Unveils New Insight To The Madness Of King George III 2Health News:Experts Insist That Neonatal Herpes Be Reported Regularly 2
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... gynecologic cancers and women,s health, has appointed Holly ... Managed Markets. Ms. Bauzon has a proven ... payer coverage for laboratory services companies. She has more ... PerkinElmer, Inc., where she held the position of Director, ...
(Date:8/21/2014)... 2014 /CNW/ - Eisai Limited is pleased to support the ... comic book available in Canada . The ... to educate children and their parents about epilepsy, the most ... more than 300,000 Canadians. Eisai is guided by a corporate ... which the patient is central – there was a need ...
(Date:8/21/2014)... 21, 2014 /PRNewswire-iReach/ -- ScriptPro has been certified ... its Common Security Framework (CSF). According to ... Manager, "We appreciate this rigorous, top-to-bottom audit. Security-minded ... this certification signifies. Our business partners need to ... CSF CERTIFICATION PROCESS: ScriptPro,s internal security processes and ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2ScriptPro Achieves HITRUST Certification 2
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that Arthur T. Sands, ... will present at the Stifel Nicolaus Healthcare Conference in ... Eastern Time.  Dr. Sands will provide an overview on ...
... 2011 Reportlinker.com announces that a new market ... Pharmaceutical Distributors - Global ... This register contains information about 2800 ... register includes the following information about the ...
Cached Medicine Technology:Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference 2
For the quantitative in vitro determination of Inorganic Phosphorous in serum....
For the quantitative in vitro determination of total and direct bilirubin in serum or plasma....
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
For the quantitative in vitro determination of total protein in urine and c.s.f....
Medicine Products: